From common to unreported: a real-world study of adverse events to duloxetine in the treatment of osteoarthritis.

IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Jingkai Di,Likun Qi,Lujia Liu,Xinglong Xing,Yaru Liu,Chuan Xiang
{"title":"From common to unreported: a real-world study of adverse events to duloxetine in the treatment of osteoarthritis.","authors":"Jingkai Di,Likun Qi,Lujia Liu,Xinglong Xing,Yaru Liu,Chuan Xiang","doi":"10.1080/14740338.2024.2393470","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nIn a review of drug guidelines published by the International Association for the Study of Osteoarthritis, it is recommended to support the conditional use of duloxetine in patients with osteoarthritis. However, there is a lack of comprehensive research on the adverse events of duloxetine for the treatment of osteoarthritis populations.\r\n\r\nRESEARCH DESIGN AND METHODS\r\nWe used the reporting odds ratio (ROR) to determine the strength of the adverse event signal. In addition, we investigated trends in the occurrence of adverse events using the Weibull shape parameter (WSP) test.\r\n\r\nRESULTS\r\nThe results showed that 50 and 14 adverse events were detected in both Asian and American populations. Four new adverse events, Mouth ulceration, femoral neck fracture, incontinence, long QT syndrome, were identified. There was a difference in the time of adverse event induction between the North American and Asian populations (p < 0.0001). The Weibull shape parameter (WSP) test showed that the incidence of AE decreased over time.\r\n\r\nCONCLUSION\r\nOur study contributes to an in-depth understanding of the safety of duloxetine in the treatment of osteoarthritis.","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":"38 1","pages":"1-14"},"PeriodicalIF":3.0000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14740338.2024.2393470","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND In a review of drug guidelines published by the International Association for the Study of Osteoarthritis, it is recommended to support the conditional use of duloxetine in patients with osteoarthritis. However, there is a lack of comprehensive research on the adverse events of duloxetine for the treatment of osteoarthritis populations. RESEARCH DESIGN AND METHODS We used the reporting odds ratio (ROR) to determine the strength of the adverse event signal. In addition, we investigated trends in the occurrence of adverse events using the Weibull shape parameter (WSP) test. RESULTS The results showed that 50 and 14 adverse events were detected in both Asian and American populations. Four new adverse events, Mouth ulceration, femoral neck fracture, incontinence, long QT syndrome, were identified. There was a difference in the time of adverse event induction between the North American and Asian populations (p < 0.0001). The Weibull shape parameter (WSP) test showed that the incidence of AE decreased over time. CONCLUSION Our study contributes to an in-depth understanding of the safety of duloxetine in the treatment of osteoarthritis.
从常见到未报告:关于度洛西汀治疗骨关节炎不良事件的真实世界研究。
背景在国际骨关节炎研究协会发布的药物指南回顾中,建议支持骨关节炎患者有条件地使用度洛西汀。然而,目前还缺乏关于度洛西汀治疗骨关节炎人群不良事件的全面研究。研究设计与方法我们使用报告几率比(ROR)来确定不良事件信号的强度。结果表明,在亚洲和美国人群中分别发现了 50 例和 14 例不良事件。发现了四种新的不良事件,即口腔溃疡、股骨颈骨折、大小便失禁和长 QT 综合征。北美和亚洲人群发生不良事件的时间存在差异(P < 0.0001)。我们的研究有助于深入了解度洛西汀治疗骨关节炎的安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.90
自引率
3.20%
发文量
97
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Drug Safety ranks #62 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports. Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信